Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis

被引：3
|
作者：
Nishibu, Akiko [1 ,2 ]
Sakai, Erika [1 ]
Oyama, Noritaka [1 ]
Yamamoto, Toshiyuki [1 ]
机构：
[1] Fukushima Med Univ, Dept Dermatol, Fukushima, Japan
[2] Kanazawa Med Univ, Dept Dermatol, Kanazawa, Ishikawa, Japan
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2012年 / 53卷 / 02期
关键词：
bosentan; endothelin; systemic sclerosis; DIGITAL ULCERS;
D O I：
10.1111/j.1440-0960.2010.00719.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
We report a case of systemic sclerosis with interstitial pneumonia and severe pulmonary hypertension treated with bosentan, an endothelin receptor antagonist. Within a short period of administration of the bosentan the skin sclerosis improved.
引用
收藏
页码：E32 / E33
页数：2
相关论文
共 50 条
  • [1] Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis
    Cutolo, Maurizio
    Ruaro, Barbara
    Pizzorni, Carmen
    Ravera, Francesca
    Smith, Vanessa
    Zampogna, Giuseppe
    Paolino, Sabrina
    Seriolo, Bruno
    Cimmino, Marco
    Sulli, Alberto
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 881 - 886
  • [2] Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)
    Riccardi, M. T.
    Chiala, A.
    Iannone, F.
    Grattagliano, V.
    Covelli, M.
    Lapadula, G.
    REUMATISMO, 2007, 59 (02) : 135 - 139
  • [3] Bosentan in systemic sclerosis:: perspectives
    Berezne, A.
    Mouthon, L.
    Guillevin, L.
    REVUE DE MEDECINE INTERNE, 2007, 28 : S248 - S253
  • [4] Bosentan: a dual endothelin receptor antagonist
    Rubin, LJ
    Roux, S
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (07) : 991 - 1002
  • [5] Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis
    John Varga
    Current Rheumatology Reports, 2003, 5 (2) : 145 - 146
  • [6] Bosentan improves systemic sclerosis-related peripheral circulation insufficiency
    Yagi, Shusuke
    Akaike, Masashi
    Aihara, Ken-ichi
    Iwase, Takashi
    Sumitomo-Ueda, Yuka
    Yoshida, Sumiko
    Matsumoto, Toshio
    Sata, Masataka
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 147 (03) : 472 - 475
  • [7] Successful Treatment of Systemic-Sclerosis-Related Digital Ulcers with a Selective Endothelin Type A Receptor Antagonist (Sitaxentan)
    Gholam, P.
    Sehr, T.
    Enk, A.
    Hartmann, M.
    DERMATOLOGY, 2009, 219 (02) : 171 - 173
  • [8] Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study
    Nguyen, Van Anh
    Eisendle, Klaus
    Gruber, Ingrid
    Hugl, Beate
    Reider, Daniela
    Reider, Norbert
    RHEUMATOLOGY, 2010, 49 (03) : 583 - 587
  • [9] Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil
    Ambach, Andreas
    Seo, Won
    Bonnekoh, Bernd
    Gollnick, Harald
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 (10): : 888 - 891
  • [10] Pharmacotherapy of Systemic Sclerosis: focus on Bosentan
    Afshar, Kamyar
    Boyd-King, Ayana
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 253 - 262
12345